Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the second-highest quintile among peers.
BlackRock Health Sciences Opps Inv A SHSAX
- NAV / 1-Day Return 70.86 / −0.48 %
- Total Assets 8.4 Bil
-
Adj. Expense Ratio
- Expense Ratio 1.090%
- Distribution Fee Level Low
- Share Class Type Front Load
- Category Health
- Investment Style Large Blend
- Min. Initial Investment 1,000
- Status Open
- TTM Yield 0.23%
- Turnover 29%
USD | NAV as of Jul 02, 2024 | 1-Day Return as of Jul 02, 2024, 10:17 PM GMT+0
Morningstar’s Analysis SHSAX
Will SHSAX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 49.3
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Eli Lilly and Co | 9.56 | 781.2 Mil | Healthcare |
UnitedHealth Group Inc | 8.46 | 691.2 Mil | Healthcare |
Boston Scientific Corp | 5.39 | 439.9 Mil | Healthcare |
AbbVie Inc | 4.97 | 405.5 Mil | Healthcare |
Merck & Co Inc | 4.78 | 390.1 Mil | Healthcare |
Thermo Fisher Scientific Inc | 3.60 | 294.2 Mil | Healthcare |
Amgen Inc | 3.52 | 287.9 Mil | Healthcare |
Danaher Corp | 3.28 | 268.0 Mil | Healthcare |
Abbott Laboratories | 2.95 | 240.6 Mil | Healthcare |
Stryker Corp | 2.79 | 227.7 Mil | Healthcare |